TLC Adds New Asian Partner in Sciclone PAD Collaboration
TAIPEI, Taiwan – Drug reformulation specialist Taiwan Liposome Co. (TLC), of Taipei, Taiwan, said it granted Sciclone Pharmaceuticals Inc., of Foster City, Calif., exclusive rights to distribute Proflow, its treatment for peripheral arterial disease (PAD), in China, Macau and Hong Kong.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST